- Alzheimer’s is America’s most expensive disease, with a new diagnosis every 66 seconds
- IGC’s unique use of marijuana extracts in combination therapy for potential Alzheimer’s breakthrough shows promise
- Low market cap could make IGC a big winner for early investors
Alzheimer’s disease is one of the greatest medical, ethical, and financial challenges facing society today. Currently, more than 5.3 million Americans and their families have to deal with Alzheimer’s disease, and projections suggest that number will nearly triple to 14 million Americans by 2050. Globally, the figures are even more staggering, with about 47 million people worldwide currently diagnosed and projections at 132 million in less than three decades. Right now, someone in America develops Alzheimer’s every 66 seconds, and soon, this deadly diagnosis is expected to occur every 33 seconds.
Alzheimer’s is already the country’s most expensive disease. In 2016 U.S. costs totaled $236 billion and global costs exceeded $600 billion. These figures will skyrocket unless scientists develop new approaches to prevent or cure this insidious disease. Given the magnitude of the problem, pharmaceutical companies are scrambling to find ways to mitigate the disease’s devastation.
With so much on the line, it’s no wonder that Wall Street has already started to place bets on who might be a winner in this race. In this vein, Goldman Sachs recently highlighted Biogen (NASDAQ: BIIB) and its lead pipeline Alzheimer’s drug as one of the first to possibly prevent or slow the progression of the disease (http://nnw.fm/H4Py2). Goldman pegged potential drug sales at over $12 billion and targeted the $60 billion market cap stock at a 17 percent premium, if successful. However, everyone knows there are no guaranteed winners in this race. A broad spectrum of options must be considered if investors want to participate in the enormous upside potential of an effective Alzheimer’s treatment.
One compelling candidate with a promising patent pending Alzheimer’s treatment protocol and ridiculously low market valuation is India Globalization Capital (NYSE MKT: IGC). IGC is a pioneer in the development of new classes of phytocannabinoid pharmaceuticals with broad therapeutic applications for both humans and animals. IGC’s pipeline of patented and patent pending therapeutics include treatments for pain, post-traumatic stress disorder, cachexia, neurologic disorders, Parkinson’s, and, now, Alzheimer’s disease.
IGC recently acquired the exclusive rights to its novel THC-based treatment for Alzheimer’s disease from the University of South Florida (http://www.igcinc.us/alzheimers-disease/). The patent identifies discovery of a new pathway in which low doses of THC bind to amyloid beta plaques and prevent those plaques from aggregating on neurons, which is exactly what occurs in Alzheimer’s disease and causes cognitive decline.
IGC plans to enter clinical trials this year on its potential cannabis-based blockbuster treatment for Alzheimer’s, as well as on the company’s primary pipeline of other major therapeutics that address large market maladies. Any one of these trials could provide breakthrough treatments for previously untreatable disease. With a market capitalization currently around $10 million, IGC is one very interesting bet investors may want to place in this race for an effective Alzheimer’s treatment. Any positive results from the clinical trials could easily catapult valuation and make IGC a big winner for early investors.
For more information, please visit www.IGCInc.us
More from CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
For more information please visit https://www.CannabisNewsWire.com